This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
VWR Corp Continues its Acquisition Spree with MESM Buyout
by Zacks Equity Research
VWR Corporation (VWR) recently acquired a global provider of laboratory and medical equipment and ancillary supplies to clinical trials, MESM Ltd.
Medtronic (MDT) Less-Invasive HVAD Pump Results Positive
by Zacks Equity Research
Medtronic plc (MDT), a leading name in medical device space, recently presented preliminary results from its HVAD LATERAL study.
Medtronic HVAD System Results Positive for Long-Term Therapy
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently released results of its ENDURANCE Supplemental trial in regard to HVAD System.
IDEXX Laboratories' CAG Revenues Solid, Competition Rife
by Zacks Equity Research
On Apr 5, we issued an updated research report on Delaware NJ-based IDEXX Laboratories, Inc. (IDXX).
Walgreens Boots (WBA) Meets Q2 Earnings, Retains EPS View
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.36 in second-quarter fiscal 2017, up 6.1% year over year.
Walgreens, Prime Form Central Specialty & Mail Service Company
by Zacks Equity Research
Walgreens Boots Alliance (WBA), in a partnership with pharmacy benefit manager (PBM) Prime Therapeutics LLC, recently formed a combined central specialty pharmacy and mail services company AllianceRx .
NuVasive Receives FDA 510(k) Clearance in Cervical Spine
by Zacks Equity Research
NuVasive Inc. (NUVA) received the U.S. FDA's 510(K) clearance for one of its spine products.
Amedisys to Buy East Tennessee to Expand in Personal Care
by Zacks Equity Research
Amedisys Inc. (AMED) recently signed a definitive agreement to buy substantially all of the assets of a Knoxville, TN-based personal care provider, East Tennessee Personal Care Service.
Boston Scientific (BSX) Inks Agreement to Acquire Symetis SA
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently signed a definitive agreement to acquire Switzerland-based Symetis SA for $435 million in up-front cash, in a bid to fortify its structural heart business in Europe.
Abbott's St Jude Buyout to Boost Business, Risks Remain
by Zacks Equity Research
On Mar 31, we updated our research report on medical device major, Abbott Laboratories (ABT).
Genomic Health's GPS Predicts Metastatic Prostate Cancer
by Zacks Equity Research
Genomic Health, Inc. (GHDX), a global cancer company, recently unveiled positive results regarding Oncotype DX Genomic Prostate Score (GPS).
NuVasive (NUVA) Gets FDA 510(k) Clearance for CoRoent System
by Zacks Equity Research
Leading medical device company NuVasive, Inc. (NUVA) recently announced the receipt of U.S. FDA 510(k) clearance for its CoRoent Small Interbody System.
QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics
by Zacks Equity Research
QIAGEN N.V. (QGEN) launched ipsogen JAK2 RGQ PCR Kit in the U.S, following the Food and Drug Administration's (FDA) approval.
Integra LifeSciences Expands Cadence System Commercially
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART), a global medical technology company, recently announced full commercial expansion of its Cadence Total Ankle System.
5 Biggest Winners from the Obamacare Replacement Bill Pushback
by Swarup Gupta
This setback was largely an outcome of the lack of consensus among various factions of the GOP.
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
by Zacks Equity Research
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
Obamacare Repeal Vote Looms: What Investors Need to Know
by Madeleine Johnson
Investors' eyes will be focused on Congress today, as the House is scheduled to vote on the American Healthcare Act (AHCA). Whether you think it???s "Obamacare Lite" or "dead on arrival" like Sen. Rand Paul, the AHCA has certainly made an impact on Wall Street, as well as the entire healthcare industry since its announcement.
OraSure Technologies (OSUR) In Focus: Stock Jumps 8.4%
by Zacks Equity Research
OraSure Technologies, Inc. (OSUR) moved big last session, as its shares jumped over 8% on the day.
Top 5 Efficient Stocks to Buy Right Now
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns.
Your Guide to the Stock Winners & Losers of Trump's Obamacare Replacement Bill
by Madeleine Johnson
Whether you think it???s "Obamacare Lite," "Obamacare 2.0," "dead on arrival" like Rand Paul, or you actually like the bill, the American Healthcare Act (AHCA) has certainly made an impact on the entire healthcare industry since its announcement. Who are the stock winners and losers so far? And who will be affected if it's passed?
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems
4 Big Winners of Trump's Healthcare Plan
by Swarup Gupta
The new healthcare legislation has its own sets of winners and losers.
Hit ETFs & Stocks from the Top Sector of February
by Sweta Killa
Inside the best performing sector of February and their best ETFs & stocks.
5 Best Efficient Stocks to Buy in March
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Top Ranked Momentum Stocks to Buy for February 27th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, February 27th: